Replies to post #13329 on DNAprint Genomics (DNAG)

[worktoplay]

Interesting choice of ADR's that Eudragene has chosen to tackle first. Mr. Paul McKeigue, familiar to all DNAP investors, is leading the effort, but as you can also see many countries are involved:

http://www.Eudragene.com

Here's an excerpt:

EUDRAGENE

European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions

This project is funded with support from the European Union from 2003-06 (Project number: QLRT-2001-02757)

Coordinator: Paul McKeigue <[e-mail]> Professor of Metabolic and Genetic Epidemiology, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, UK

Tel: [phone]

Objectives

The specific objectives of this study is to establish a collection of DNA samples as a resource for studying genes which influence serious or adverse drug reactions (ADRs). Identifying genes that influence susceptibility to adverse reactions will advance understanding of the basis of adverse drug reactions and may also lead to the development of tests that can predict individual susceptibility to adverse reactions, with obvious benefits to human health.

At least 500 cases of each ADR will be collected, together with an equal number of healthy volunteers. The co-ordinating centre will manage the database, and will make samples freely available to academic and industry-based researchers throughout Europe. The collection will be extended to include more ADRs after the first 1-2 years, based on problems of current concern.....

Later,
W2P